17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
Compounds having the structure, their salts or N-oxide derivatives: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.
1. A compound, a salt or an N-oxide thereof, having the following molecular formula:
wherein n is an integer from 1 to 2;
wherein R 2 is selected from the group consisting of hydrogen and fluoro;
wherein R 3 is selected from the group consisting of hydrogen, cyano, chloro, methoxy, ethoxy, nitro, and propynyl;
wherein R 4 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, cyano, amino, cyclopropyl, and C 1 alkyl;
wherein said cyclopropyl and C 1 alkyl in R 4 are optionally substituted with fluoro;
wherein R 11β , is selected from the group consisting of hydrogen, fluoro, C 1 -C 2 alkyl, and C 2 alkenyl;
wherein R 17α and R 17β are independently selected from the group consisting of hydroxyl, methoxy and -A-A′-Ar
A and A′ being spacer groups independently selected from the group consisting of absent —CH 2 —, —CHF—, —CH(CH 3 )—, propynylene, and
(B and C being independently selected from the group consisting of hydrogen, fluoro, and methyl),
and Ar being selected from the group consisting of:
(D being selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl, ethyl and methoxy and E being selected from the group consisting of hydrogen, cyano and methyl);
(f is CH or nitrogen);
and
(G being selected from the group consisting of cyano, —CONR 1 R 2 (R 1 and R 2 are independently selected from the group consisting of hydrogen and methyl) and —SOCH 3
wherein when R 17α is hydroxyl or methoxy, R 17β is -A-A′-Ar, and when R 17β is hydroxyl or methoxy, R 17α is -A-A′-Ar.
2. The compound, a salt or an N-oxide thereof, of claim 1 , having the following molecular formula:
wherein n is an integer from 1 to 2;
wherein R 4 is selected from the group consisting of fluoro, chloro, and methyl;
wherein R 17α and R 17β are independently selected from the group consisting of hydroxyl and —CH 2 —Ar
Ar being selected from the group consisting of:
(D being selected from the group consisting of hydrogen, fluoro, and methyl);
wherein when R 17α is hydroxyl or methoxy, R 17β is —CH 2 —Ar, and when R 17β is hydroxyl or methoxy, R 17α is —CH 2 —Ar.
3. An antiandrogenic compound having a molecular formula selected from the group consisting of:
4. A Selective Androgen Receptor Modulator having a molecular formula selected from the group consisting of:
5. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of at least one compound, or a salt or an N-oxide thereof, having the following molecular formula:
wherein n is an integer from 1 to 2;
wherein R 2 is selected from the group consisting of hydrogen and fluoro;
wherein R 3 is selected from the group consisting of hydrogen, cyano, chloro, methoxy, ethoxy, nitro, and propynyl;
wherein R 4 is selected from the group consisting of hydrogen, fluoro, chloro, bromo, cyano, amino, cyclopropyl, and C 1 alkyl, wherein said cyclopropyl and C 1 alkyl are optionally-substituted with fluoro;
wherein R 11β , is selected from the group consisting of hydrogen, fluoro, C 1 -C 2 alkyl, and C 2 alkenyl;
wherein R 17α and R 17β are independently selected from the group consisting of hydroxyl, methoxy and -A-A′-Ar
A and A′ being spacer groups independently selected from the group consisting of absent —CH 2 —, —CHF—, —CH(CH 3 )—, propynylene, and
(B and C being independently selected from the group consisting of hydrogen, fluoro, and methyl),
and Ar being selected from the group consisting of:
(D being selected from the group consisting of hydrogen, fluoro, chloro, bromo, methyl, ethyl and methoxy and E being selected from the group consisting of hydrogen, cyano and methyl);
(f is CH or nitrogen);
and
(G being selected from the group consisting of cyano, —CONR 1 R 2 (R 1 and R 2 are independently selected from the group consisting of hydrogen and methyl) and —SOCH 3
wherein when R 17α is hydroxyl or methoxy, R 17β is -A-A′-Ar, and when R 17β is hydroxyl or methoxy, R 17α is -A-A′-Ar.
6. The pharmaceutical composition of claim 5 wherein the compound, a salt or an N-oxide thereof, has the following molecular formula:
wherein n is an integer from 1 to 2;
wherein R 4 is selected from the group consisting of fluoro, chloro, and methyl;
wherein R 17α and R 17β are independently selected from the group consisting of hydroxyl and —CH 2 —Ar
Ar being selected from the group consisting of:
(D being selected from the group consisting of hydrogen, fluoro, and methyl);
wherein when R 17α is hydroxyl or methoxy, R 17β is —CH 2 —Ar, and when R 17β is hydroxyl or methoxy, R 17α is —CH 2 —Ar.
7. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of at least one antiandrogenic compound having a molecular formula selected from the group consisting of:
8. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of at least one Selective Androgen Receptor Modulator having a molecular formula selected from the group consisting of:
9. A method of treating prostate cancer, comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound or pharmaceutical composition of any one of claims 1 and 5 .
10. The method of claim 9 further comprising orchiectomy or administering an LHRH agonist or antagonist.
11. A method of treating benign prostatic hyperplasia comprising administering to a patient in need of such treatment, a therapeutically effective amount of the compound or pharmaceutical composition of any one of claims 1 and 5 .
12. A method of treating polycystic ovarian syndrome comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound or pharmaceutical composition of any one of claims 1 and 5 .
13. A method of treating acne, seborrhea, hirsutism or androgenic alopecia comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound or pharmaceutical composition of any one of claims 1 and 5 .
14. A method of treating precocious puberty comprising administering to a male or female patient in need of such treatment a therapeutically effective amount of the compound or pharmaceutical composition of any one of claims 1 and 5 .
15. The method of claim 14 comprising administering to a male patient a therapeutically effective amount of an LHRH agonist or antagonist.
16. The compound of claim 1 possessing a tissue-specific antiandrogenic activity and a tissue-specific androgenic activity.
17. The pharmaceutical composition of claim 5 wherein the active compound possesses a tissue-specific antiandrogenic activity and a tissue-specific androgenic activity.
18. A method of treating diseases related to loss of androgenic stimulation, selected from muscle atrophy and weakness, skin atrophy, bone loss, anemia, arteriosclerosis, cardiovascular disease, loss of energy, type 2 diabetes and abdominal fat accumulation comprising administering to a patient in need of such treatment a therapeutically effective amount of the compound or pharmaceutical composition of any one either of claim 1 or 5 .